ExThera Medical Receives CE Mark Approval for its Seraph ® 100 Blood Filter
Thursday, August 08, 2019
ExThera Medical Corporation today announced that it has received CE Mark approval for its Seraph ® 100 Microbind ® Blood Affinity Blood Filter (Seraph 100)for the reduction of pathogens during bloodstream infections (BSI). This CE marking means that the Seraph 100 meets the requirements for safety and performance of medical devices in the European Economic Area (EEA), and can be used as an adjunct in the context of an anti-infective treatment. It gives ExThera access to a market of 500 million people. In October 2019, ExThera plans to begin shipping Seraph 100 for clinical use in some EU member states, providing a new treatment option for a large population of patients at risk. Distributors for Italy, Germany and other EU countries will be announced in early September.
Bloodstream infections are one of the leading causes of death in the world, with a mortality rate of up to 50%. In Europe, the annual incidence rate is estimated at 1.2 million. In addition to rapid and effective diagnostic tests, therapeutic products are needed to successfully treat those infections for which every hour of delay in effective treatment can increase mortality by 7%. In addition, it is extremely difficult to quickly reduce pathogens during drug-resistant infections, which are increasingly common and are expected to reach 10 million people per year by 2050.
As a broad-spectrum absorbent blood filter, Seraph 100 is a new option for the treatment of bloodstream infections. While existing devices only remove the molecules , ie cytokines and / or endotoxins, Seraph 100 can also rapidly reduce the concentration of bacteria, viruses and fungi in whole blood. In preclinical and clinical trials, Seraph 100 has shown that it is able to significantly reduce the concentration of susceptible and drug-resistant pathogens , providing a long-awaited backup treatment for bloodstream infections.
In March 2019, Dr. Stefan Büttner from the Department of Nephrology, Dialysis and Kidney Transplantation at the University Hospital Frankfurt presented the results of his research at the International Symposium on Critical Care and Emergency Medicine (International Symposium). ISICEM), highlighting the excellent clinical results achieved with Seraph 100, including the safe treatment of bacteremia during dialysis.
" Today marks a turning point in the advancement of the treatment of bloodstream infections, and this is the result of years of intensive research, development and investment, " said Bob Ward, NAE, President and Chief Executive Officer. direction of ExThera. " Seraph 100 is an innovative treatment that can quickly and effectively treat infections that may pose a devastating risk to patients. We look forward to the continued success of Seraph 100 in Europe, and will demonstrate its potential to help healthcare providers and their patients around the world . "
" Bloodstream infections are an ongoing challenge for health care providers around the world, with the potential for catastrophic consequences for the patient, often leading to sepsis and even death if not treated effectively, " he said. Professor and Dr. Jan T. Kielstein, FASN, FERA, Director of Medical Clinic V: Nephrology, Rheumatology and Blood Purification, University Teaching Hospital, Braunschweig, Germany. "The Seraph 100 adds to our clinical arsenal an essential tool that can be used to treat a wide range of infections, including those that have proven to be resistant to drugs. This is an option we could not use before and we are delighted that it is now available to us . "
According to consultant Kathleen White, former Vice President and Chief Operating Officer of ExThera, " The ExThera team did an amazing job designing, testing and obtaining regulatory approval for the Seraph 100, as well as by obtaining the certification of its Quality Management System. I would like to thank them, our consultants and our clinical collaborators for their hard work and dedication to this revolutionary product . "
About Seraph and ExThera Medical
Headquartered in the San Francisco Bay Area and Vaals, Netherlands, ExThera is a privately held medical device company that develops innovative single-use blood filters capable of capturing a broad range of blood pathogens total. The unique design of the Seraph and area highly compatible with blood, developed for the first time at the Karolinska Institute in Stockholm v rapidly reduces the concentration of bacteria, viruses, fungi and mediators of sepsis resistant anddrug-sensitive in the blood taken continuously from the patient and returned to it. ExThera develops therapeutic products for the treatment of patients in hospital, on the battlefield or during epidemics. Led by an accomplished management team with extensive experience in devices and biomaterials in contact with blood, the company is solidly protected by its patents and growing body of data from independent laboratory studies (these include the company's participation in DARPA's Dialysis-Like Therapeutics program, which earned it the title of best performer), and its successful clinical trial in the EU.
For more information, visit www.extheramedical.com .
Disclaimer:All information in this press release is from reliable and plausible sources that have not been independently reviewed. There are no warranties or endorsements, and no liability or liability is assumed for their accuracy or completeness. To the extent permitted by applicable law, no liability of any kind whatsoever is assumed for any direct or indirect loss resulting from the release of this press release or its contents. This news release contains forward-looking statements with respect to events, trends and business prospects that may affect our future results of operations and financial position. These statements are subject to risks and uncertainties that may cause our results and financial position to differ materially. The resulting investment and / or income may go up or down. A total loss is possible. Persons in possession of this press release are requested to obtain information about potential legal limitations and to respect them accordingly. We assume no responsibility for the revision or updating of any forward-looking statement contained in this news release, so as to reflect events, trends or circumstances occurring after the date of this press release. The resulting investment and / or income may go up or down. A total loss is possible. Persons in possession of this press release are requested to obtain information about potential legal limitations and to respect them accordingly. We assume no responsibility for the revision or updating of any forward-looking statement contained in this news release, so as to reflect events, trends or circumstances occurring after the date of this press release. The resulting investment and / or income may go up or down. A total loss is possible. Persons in possession of this press release are requested to obtain information about potential legal limitations and to respect them accordingly. We assume no responsibility for the revision or updating of any forward-looking statement contained in this news release, so as to reflect events, trends or circumstances occurring after the date of this press release. Persons in possession of this press release are requested to obtain information about potential legal limitations and to respect them accordingly. We assume no responsibility for the revision or updating of any forward-looking statement contained in this news release, so as to reflect events, trends or circumstances occurring after the date of this press release. Persons in possession of this press release are requested to obtain information about potential legal limitations and to respect them accordingly. We assume no responsibility for the revision or updating of any forward-looking statement contained in this news release, so as to reflect events, trends or circumstances occurring after the date of this press release.
The text of the press release resulting from a translation must in no way be considered official. The only version of the release that is authentic is that of the release in its original language. The translation will always have to be confronted with the source text, which will make jurisprudence.
contacts
ExThera Medical Europe
Carla Kikken-Jussen
carla@extheramedical.com
ExThera Medical United States
Galit Gelman
Galit@extheramedical.com
Media
Heather Linville
media@extheramedical.com